

Stanford

Jordan Goldstein

Instructor, Medicine - Oncology

Bio

ACADEMIC APPOINTMENTS

- Instructor, Medicine - Oncology

HONORS AND AWARDS

- FDA-AACR Oncology Educational Fellow, American Association for Cancer Research (2024 - 2025)
- Research Training Award for Fellows, American Society of Hematology (2024 - 2025)
- Lymphoma Scientific Research Mentorship Program Errol Cook Memorial Scholar, Lymphoma Research Foundation (2024 - 2026)
- Abstract Achievement Award, American Society of Hematology (2024)
- Abstract Achievement Award, American Society of Hematology (2023)
- HONORS Award, American Society of Hematology (2020)
- Innovative Oncology Research Travel Award, Emory University (2017)
- Abstract Achievement Award, American Society of Hematology (2017)

PROFESSIONAL EDUCATION

- Board Certification, American Board of Internal Medicine , Hematology (2024)
- Fellowship, Stanford University , Hematology and Medical Oncology (2024)
- Residency, NYP-Weill Cornell Medical Center , Internal Medicine (2021)
- MS, Emory University , Clinical Research (2018)
- MD, Emory University (2018)

Publications

PUBLICATIONS

- **Roadmap for developing MRD as an early endpoint for drug approval in lymphoma.** *Seminars in hematology*
Goldstein, J. S., Wang, S. X., Chamuleau, M. E., Alizadeh, A. A.
2026
- **Non-invasive Mantle Cell Lymphoma risk stratification by inference of tumor proliferation from cfDNA**
Ashtari, A., Mutter, J., Tessoulin, B., Rossi, C., Boegeholz, J., Goldstein, J., Klanova, M., Kuehn, J., Alig, S., Schroers-Martin, J., Liu, C., Olsen, M., Kang, et al
ELSEVIER.2025: 1789-1790
- **Spatial anatomical genomic heterogeneity and aberrant somatic hypermutation define clonal evolution pathways that predict treatment resistance in aggressive B-cell lymphomas**
Goldstein, J., Wang, S., Tessoulin, B., Liu, C., Scherer, F., Le Gouill, S., Chamuleau, M., Nijland, M., Diehn, M., Kurtz, D., Alizadeh, A.
ELSEVIER.2025: 354-355
- **Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*

- Roschewski, M., Kurtz, D. M., Westin, J. R., Lynch, R. C., Gopal, A. K., Alig, S. K., Sworder, B. J., Cherng, H. J., Kuffer, C., Blair, D., Brown, K., Goldstein, J. S., Schultz, et al
2025: 101200JCO2501534
- **Beyond Trial and Error: A Mathematical Model Wrangles DLBCL Heterogeneity Toward Optimizing Combination Therapy.** *Blood cancer discovery*
Goldstein, J. S., Phillips, N. A., Alizadeh, A. A.
2025: OF1-OF4
 - **Anatomic Genetic Heterogeneity Is Uncovered By Concurrent Cell-Free DNA and Tissue Profiling and Predicts Treatment Resistance in Diffuse Large B-Cell Lymphoma**
Goldstein, J. S., Scherer, F., Sworder, B. J., Diehn, M., Kurtz, D., Alizadeh, A. A.
ELSEVIER.2024: 4357-4358
 - **Baseline Prognostic Factors Do Not Predict End of Treatment Ctdna MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL**
Goldstein, J. S., Roschewski, M., Kim, W., Yoon, S., Kim, S., Westin, J. R., Lynch, R. C., Alig, S. K., Close, S., Chabon, J., Rossi, D., Wilson, W. H., Kurtz, et al
ELSEVIER.2024: 651-652
 - **Ultrasensitive Circulating Tumor DNA MRD Status Predicts Treatment Failure & Complements PET/CT throughout Treatment for Early and Advanced Stage Classic Hodgkin Lymphoma**
Boegeholz, J., Rossi, C., Goldstein, J. S., Alig, S. K., Garofalo, A., Esfahani, M., Schroers-Martin, J. G., Liu, C., Olsen, M., Kang, X., Tian, F., Kurtz, D., Andre, et al
ELSEVIER.2024: 565-566
 - **The Clinical Impact and Cost-Effectiveness of PET-Based and Ctdna-Based Evaluation at End-of-Therapy after Frontline Treatment of DLBCL**
Kambhampati, S., Goldstein, J. S., Buller, S., Roschewski, M., Alizadeh, A. A., Thiruvengadam, N.
ELSEVIER.2024: 2276-2277
 - **Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling**
Rossi, C., Boegeholz, J., Goldstein, J. S., Shi, S., Su, S., Tessoulin, B., Alig, S. K., Garofalo, A., Esfahani, M., Schroers-Martin, J. G., Liu, C., Olsen, M., Kang, et al
ELSEVIER.2024: 853-854
 - **ViPOR's Venom - Rationally Targeting DLBCL with Precision.** *The New England journal of medicine*
Goldstein, J. S., Alizadeh, A. A.
2024; 390 (23): 2209-2211
 - **Ultrasensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) detection in early stage non-small cell lung cancer (NSCLC)**
Isbell, J. M., Goldstein, J., Hamilton, E. G., Liu, S., Eichholz, J., Buonocore, D. J., Rusch, V. W., Bott, M., Molena, D., Rocco, G., Yang, S., Rudin, C. M., Jones, et al
LIPPINCOTT WILLIAMS & WILKINS.2024
 - **Optimizing Circulating Tumor DNA Limits of Detection for DLBCL during First Line Therapy**
Goldstein, J., Kim, W., Yoon, S., Kim, S., Roschewski, M., Westin, J., Lynch, R. C., Alig, S. K., Close, S., Chabon, J. J., Rossi, D., Wilson, W. H., Diehn, et al
AMER SOC HEMATOLOGY.2023
 - **Novel agents in relapsed/refractory diffuse large B-cell lymphoma.** *Hematological oncology*
Varma, G., Goldstein, J., Advani, R. H.
2023; 41 Suppl 1: 92-106